Insulet has been a great trade. While the S&P 500 was flat, the stock price has climbed by 14.6% to $265.87 per share. This ...

A randomized study from Insulet of adults and children with Type 1 diabetes found that moving from multiple daily injections ...

Insulet Corporation PODD has witnessed strong momentum in the past year. Shares of the company have risen 62.9% compared with 9.9% growth of the industry during the same time frame. The S&P 500 ...

Data from a controlled trial indicates that patients who switched from daily insulin injections to its Omnipod 5 automated ...

Let’s dig into the relative performance of Insulet (NASDAQ:PODD) and its peers as we unravel the now-completed Q4 patient ...

Shares of Insulet Corp. PODD slipped 1.74% to $260.27 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.33% to 5,693.31 and ...

Just shy of two years after a C-suite reorganization at Insulet, Mark Field has left his position as the inaugural chief ...

This was the stock's second consecutive day of gains.

Insulet shows bullish trends with strong growth, favorable Wall Street ratings, and a 3.2:1 reward-risk ratio. Read more on ...

Insulet (Nasdaq:PODD) announced today that SVP and Chief Technology Officer Mark Field is departing the company.

Envestnet Portfolio Solutions Inc. increased its holdings in shares of Insulet Co. (NASDAQ:PODD – Free Report) by 2.3% during ...

Insulet Corporation PODD has witnessed strong momentum in the past year. Shares of the company have risen 62.9% compared with 9.9% growth of the industry during the same time frame. The S&P 500 ...